Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
NSCLC Stage IV · NSCLC, Recurrent
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The University of Kansas Cancer Center (KUCC), Fairway, Kansas, United States
The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
Study leads
Chao Huang, MD
Principal Investigator
The University of Kansas